Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.65 |
| ▸ | LTA4H | P09960 | 5/20 | 0.64 |
| ▸ | DPP4 | P27487 | 4/20 | 0.64 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.64 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.64 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.64 |
| ▸ | FAP | Q12884 | 2/20 | 0.64 |
| ▸ | TACR1 | P25103 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31164827 | 1.00 | ACE (0.65) | ACELTA4HDPP4DPP8DPP9 | |
| SCHEMBL28785114 | 1.00 | ACE (0.65) | ACELTA4HDPP4DPP8DPP9 | |
| SCHEMBL2879742 | 1.00 | ACE (0.65) | ACELTA4HDPP4DPP8DPP9 | |
| SCHEMBL6436643 | 0.96 | ACE (0.70) | ACELTA4HDPP4DPP8DPP9 | |
| SCHEMBL3726264 | 0.96 | ACE (0.70) | ACELTA4HDPP4DPP8DPP9 | |
| SCHEMBL5900809 | 0.96 | ACE (0.70) | ACELTA4HDPP4DPP8DPP9 | |
| SCHEMBL7375090 | 0.96 | ACE (0.70) | ACELTA4HDPP4DPP8DPP9 | |
| SCHEMBL31026624 | 0.96 | ACE (0.70) | ACELTA4HDPP4DPP8DPP9 | |
| SCHEMBL3726263 | 0.96 | ACE (0.70) | ACELTA4HDPP4DPP8DPP9 | |
| SCHEMBL29666849 | 0.96 | ACE (0.70) | ACELTA4HDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7731949-B2 | — | — | 2010-06-08 | — | — | US | disclosed |
| EP-2076264-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF HCV | XTL Biopharmaceuticals LTD (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090041723-A1 | Compounds and methods for treatment of HCV | XTL BIOPHARMACEUTICALS LTD. (IL) | 2009-02-12 | — | — | US | disclosed |
| WO-2008048589-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF HCV | XTL BIOPHARMACEUTICALS LTD (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041723-A1 | Compounds and methods for treatment of HCV | HAVCR2, EIF2AK2, MAVS | ACE 241/4885LTA4H 1974/4885DPP4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.